[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO1989003422A1 - Synthetic gene - Google Patents

Synthetic gene Download PDF

Info

Publication number
WO1989003422A1
WO1989003422A1 PCT/GB1988/000831 GB8800831W WO8903422A1 WO 1989003422 A1 WO1989003422 A1 WO 1989003422A1 GB 8800831 W GB8800831 W GB 8800831W WO 8903422 A1 WO8903422 A1 WO 8903422A1
Authority
WO
WIPO (PCT)
Prior art keywords
gct
dna
ggc
acc
aac
Prior art date
Application number
PCT/GB1988/000831
Other languages
French (fr)
Inventor
Richard Mark Edwards
Original Assignee
British Bio-Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Bio-Technology Limited filed Critical British Bio-Technology Limited
Publication of WO1989003422A1 publication Critical patent/WO1989003422A1/en
Priority to NO90901588A priority Critical patent/NO901588L/en
Priority to FI901763A priority patent/FI901763A0/en
Priority to DK088290A priority patent/DK88290A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)

Definitions

  • This invention relates to synthetic genes coding for streptavidin.
  • Streptavidin is a 60 kD protein isolated from Streptomyces avidinii that binds extremely tightly to the vitamin biotin with a dissociation constant of about 10 -15 M. Streptavidin is composed of four identical subunits of 15 kD and binds 4 mole biotin per mole of protein. It is structurally related to the protein avidin, a biotin binding protein isolated from chicken egg whites.
  • Streptavidin has particular utility in that it can be readily conjugated to a range of other proteins such as horseradish peroxidase and alkaline phosphatase. This has allowed the development of sensitive detection systems for biotinylated oligonucleotides, antibodies and other binding proteins with application in the analysis of DNA, RNA, protein and carbohydrates.
  • the natural gene for streptavidin has been described and was found to encode a protein of 183 amino acids which included a typical leader sequence of 24 amino acids. The N-terminus of the mature protein was found to correspond to residue 25 of the deduced sequence.
  • the amino acid sequence of mature streptavidin deduced from the gene sequence was used as the basis of the design for the synthetic streptavidin genes of the present invention and is shown in Figure 1.
  • the binding of streptavidin to biotin was described in 1963 by Chaiet et al. (Agents Chemother. 3, 28-32).
  • the cloning of. the natural streptavidin gene and its sequence together with the deduced streptavidin amino acid sequence is taught by Argarana et al. (Nucleic Acids Res. 14 1871-1882 (1986)).
  • the production of streptavidin-like polypeptides is disclosed in EP-A-0198015 (Biogen NV) .
  • the present invention relates to a synthetic streptavidin gene which is distinct from the natural streptavidin gene and has advantages in the ease with which it can be modified due to the presence of useful restriction sites.
  • DNA including the following sequence:
  • Codons are those that are favoured by E. coli but it is expected that the DNA would be suitable for expression in other organisms including yeast and mammalian cells.
  • DNA sequences in accordance with the invention encode the entire mature streptavidin protein together with the required initiator methionine residue but lack the leader sequence present in the natural gene. It is envisaged that the leader sequence appropriate to the expression system, of choice would be added to the synthetic gene as required or omitted to allow for intracellular expression of the gene.
  • a genetic construct comprising DNA according to the first or second aspect or a fragment thereof.
  • the fragment may comprise at least 10, 20, 30, 40 or 50 nucleotides.
  • a genetic construct in accordance with the third aspect may be a vector, such as a plasmid, cosmid or phage.
  • a genetic construct in accordance with the third aspect may be a chimeric gene composing all or a fragment of DNA according to the first or second aspect fused to any other sequence of DNA so as to result in a sequence capable of encoding a hybrid protein possessing biotin binding activity.
  • a process for the preparation of DNA in accordance with the first or second aspect or a genetic construct in accordance with the third aspect comprising coupling successive nucleotides and/or ligating appropriate oligomers.
  • the invention also relates to other nucleic acid (including RNA) either corresponding to or complementary to DNA in accordance with the first or second aspects.
  • FIG 1 shows the amino acid sequence of streptavidin
  • Figure 2 shows a sequence of a streptavidin synthetic gene in accordance with the invention incorporating a summary of restriction sites
  • Figure 3 shows a sequence of a synthetic streptavidin gene in accordance with the invention divided into oligonucleotides
  • Figure 4 shows a summary of an assembly procedure used.
  • oligomers oligodeoxyribonucleotides
  • the division was such as to provide 7 base cohesive ends after annealing complementary pairs of oligomers.
  • the end points of the oligomers were chosen to minimise the potential for inappropriate ligation of oligomers at the assembly stage.
  • the oligomers were synthesised by automated solid phase phosphoramidite chemistry. Following de-blocking and removal from the controlled pore glass support the oligomers were purified on denaturing polyacrylamide gels, further purified by ethanol precipitation and finally dissolved in water prior to estimation of their concentration.
  • the ligated product was transformed into HW87 and plated on L-agar plates containing 100 meg ml -1 ampicillin. Colonies containing potential clones were then grown up in L-broth containing ampicillin at 100 meg ml -1 and plasmid DNA isolated. Positive clones were identified by direct dideoxy sequence analysis of the plasmid DNA using the 17 base universal primer, a reverse sequencing primer complementary to the opposite strand on the other side of the polylinker and some of the oligomers employed in the assembly of the gene that served as internal primers. One streptavidin clone was subsequently re-sequenced on both strands to confirm that no mutations were present.
  • oligonucleotides were synthesised by automated phosphoramidite chemistry using cyanoethyl phosphoramidtes. The methodology is now widely used and has been described (Beaucage, S.L. and Caruthers, M.H. Tetrahedron Letters 24, 245 (1981)).
  • the oligonucleotides were de-protected and removed from the CPG support by incubation in concentrated NH 3 .
  • concentrated NH 3 typically, 50 mg of CPG carrying 1 micromole of oligonueleotide was de-protected by incubation for 5 hr at 70° in 600 mcl of concentrated NH3.
  • the supernatant was transferred to a fresh tube and the oligomer precipitated with 3 volumes of ethanol. Following centrifugation the pellet was dried and resuspended in 1 ml of water. The concentration of crude oligomer was then determined by measuring the absorbance at 260 nm.
  • the bands were visualised by UV shadowing and those corresponding to the full length product cut out and transferred to micro-testubes.
  • the oligomers were eluted from the gel slice by soaking in AGEB (0.5 M ammonium acetate, 0.01 M magnesium acetate and 0.1 % SDS) overnight.
  • the AGEB buffer was then transferred to fresh tubes and the oligomer precipitated with three volumes of ethanol at -70° for 15 min.
  • the precipitate was collected by centrifugation in an Eppendorf microfuge for 10 min, the pellet washed in 80 % ethanol, the purified oligomer dried, redissolved in 1 ml of water and finally filtered through a 0.45 micron micro-filter.
  • the concentration of purified product was measured by determining its absorbance at 260 nm. 3) Kinasing of oligomers
  • oligomer 250 pmole of oligomer was dried down and resuspended in 20 mcl kinase buffer (70 mM Tris pH 7.6, 10 mM MgCl 2 , 1 mM ATP, 0.2 mM spermidine, 0.5 mM dithiothreitol). 10 u of T4 polynucleotide kinase was added and the mixture incubated at 37° for 30 min. The kinase was then inactivated by heating at 85° for 15 min.
  • Ligation products were separated using 2% low gelling temperature agarose gels in 1 X TBE buffer (0.094 M Tris pH 8.3, 0.089 M boric acid, 0.25 mM EDTA) containing 0.5 meg ml -1 ethidium bromide. 7) Isolation of ligation product
  • the band corresponding to the expected streptavidin gene ligation product was identified by reference to size markers under long wave UV illumination. The band was cut out of the gel and the DNA extracted as follows.
  • the volume of the gel slice was estimated from its weight and then melted by incubation at 65° for 10 min. The volume of the slice was then made up to 400 mcl with TE (10 mM Tris pH 8.0, 1 mM EDTA) and Na acetate added to a final concentration of 0.3 M. 10 meg of yeast tRNA was also added as a carrier. The DNA was then subjected to three rounds of extraction with equal volumes of TE equilibrated phenol followed by three extractions with ether that had been saturated with water. The DNA was precipitated with 2 volumes of ethanol, centrifuged for 10 min in a microfuge, the pellet washed in 70 % ethanol and finally dried down. The DNA was taken up in 20 mcl of TE and 2 mcl run on a 2 % agarose gel to estimate the recovery of DNA.
  • pUC18 DNA eg ATCC 37253
  • HindIII and BamHI as advised by the suppliers.
  • the digested DNA was run on an 0.8 % LGT gel and the vector band purified as described above.
  • Plasmid DNA was prepared from the colonies containing potential streptavidin clones essentially as described (Ish-Horowicz, D., Burke, J.F. Nucleic Acids Research 9 2989-2998 (1981).
  • the protocol used was essentially as has been described (Biggin, M.D., Gibson, T.J., Hong, G.F. P.N.A.S. 80 3963-3965 (1983)).
  • the method was modified to allow sequencing on plasmid DNA as described (Guo, L-H., Wu, R. Nucleic Acids Research 11 5521-5540 (1983).
  • araD139 (ara-leu) del7697 (lacIPOZY) del74 galU galK hsdR rpsL srl recA56
  • Any other standard cloning recipient such as HB101 would be adequate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Saccharide Compounds (AREA)

Abstract

Synthetic DNA coding for streptavidin includes sequence (I) and incorporates useful restriction sites at frequent intervals to facilitate the cassette mutagenesis of selected regions. Also included are flanking restriction sites to simplify the incorporation of the gene into any desired expression system.

Description

SYNTHETIC GENE
This invention relates to synthetic genes coding for streptavidin.
Streptavidin is a 60 kD protein isolated from Streptomyces avidinii that binds extremely tightly to the vitamin biotin with a dissociation constant of about 10-15 M. Streptavidin is composed of four identical subunits of 15 kD and binds 4 mole biotin per mole of protein. It is structurally related to the protein avidin, a biotin binding protein isolated from chicken egg whites.
Streptavidin has particular utility in that it can be readily conjugated to a range of other proteins such as horseradish peroxidase and alkaline phosphatase. This has allowed the development of sensitive detection systems for biotinylated oligonucleotides, antibodies and other binding proteins with application in the analysis of DNA, RNA, protein and carbohydrates.
The natural gene for streptavidin has been described and was found to encode a protein of 183 amino acids which included a typical leader sequence of 24 amino acids. The N-terminus of the mature protein was found to correspond to residue 25 of the deduced sequence. The amino acid sequence of mature streptavidin deduced from the gene sequence was used as the basis of the design for the synthetic streptavidin genes of the present invention and is shown in Figure 1. The binding of streptavidin to biotin was described in 1963 by Chaiet et al. (Agents Chemother. 3, 28-32). The cloning of. the natural streptavidin gene and its sequence together with the deduced streptavidin amino acid sequence is taught by Argarana et al. (Nucleic Acids Res. 14 1871-1882 (1986)). The production of streptavidin-like polypeptides is disclosed in EP-A-0198015 (Biogen NV) .
In order to facilitate the dissection of the structure/function relationships of streptavidin, its incorporation into expression vectors and the production of novel chimeric proteins containing streptavidin functionality an improved novel synthetic gene for the streptavidin produced by Streptomyces avidinii is sought.
It is by no means easy to predict the design of an improved streptavidin gene, since the factors that determine the expressibility of a given DNA sequence are still poorly understood. Furthermore, the utility of the gene in various applications will be influenced by such considerations as codon usage and restriction sites. The present invention relates to a synthetic streptavidin gene which is distinct from the natural streptavidin gene and has advantages in the ease with which it can be modified due to the presence of useful restriction sites.
When synthesising and assembling genes, problems have been encountered when there are inverted or direct repeats greater than eight bases long in the genetic sequence. In addition, areas of unbalanced base composition such as G/C or A/T rich regions or polypurine/polypyrimidine tracts have been found to lead to inefficient expression. The present invention seeks to overcome or at least alleviate these difficulties.
According to a first aspect of the invention, there is provided DNA coding for streptavidin and having restriction sites for the following enzymes:
EcoRI, NdeI, PstI, SalI, SacI, SnaBI, BspMI , KpnI, FspI, PflMI, DraI , BalI, BstXI, HpaI, NsiI, SpeI, NheI, BstEII, XbaI, BamHI and HindIII
According to a second aspect of the invention, there is provided DNA including the following sequence:
ATG GAC CCG TCC AAG GAC TCC AAA GCT CAG GTT TCT GCA GCC GAA GCT GGT ATC ACT GGC ACC TGG TAT AAC CAA CTG GGG TCG ACT TTC ATT GTG ACC GCT GGT GCG GAC GGA GCT CTG ACT GGC ACC TAC GAA TCT GCG GTT GGT AAC GCA GAA TCC CGC TAC GTA CTG ACT GGC CGT TAT GAC TCT GCA CCT GCC ACC GAT GGC TCT GGT ACC GCT CTG GGC TGG ACT GTG GCT TGG AAA AAC AAC TAT CGT AAT GCG CAC AGC GCC ACT ACG TGG TCT GGC CAA TAC GTT GGC GGT GCT GAG GCT CGT ATC AAC ACT CAG TGG CTG TTA ACA TCC GGC ACT ACC GAA GCG AAT GCA TGG AAA TCG ACA CTA GTA GGT CAT GAC ACC TTT ACC AAA GTT AAG CCT TCT GCT GCT AGC ATT GAT GCT GCC AAG AAA GCA GGC GTA AAC AAC GGT AAC CCT CTA GAC GCT GTT CAG CAA TAA A synthetic streptavidin gene as described above incorporates useful restriction sites at frequent intervals to facilitate the cassette mutagenesis of selected regions. Also included are flanking restriction sites to simplify the incorporation of the gene into any desired expression system.
Codons are those that are favoured by E. coli but it is expected that the DNA would be suitable for expression in other organisms including yeast and mammalian cells.
Certain DNA sequences in accordance with the invention encode the entire mature streptavidin protein together with the required initiator methionine residue but lack the leader sequence present in the natural gene. It is envisaged that the leader sequence appropriate to the expression system, of choice would be added to the synthetic gene as required or omitted to allow for intracellular expression of the gene.
According to a third aspect of the invention, there is provided a genetic construct comprising DNA according to the first or second aspect or a fragment thereof. The fragment may comprise at least 10, 20, 30, 40 or 50 nucleotides. A genetic construct in accordance with the third aspect may be a vector, such as a plasmid, cosmid or phage. Alternatively or in addition, a genetic construct in accordance with the third aspect may be a chimeric gene composing all or a fragment of DNA according to the first or second aspect fused to any other sequence of DNA so as to result in a sequence capable of encoding a hybrid protein possessing biotin binding activity. According to a fourth aspect of the invention, there is provided a process for the preparation of DNA in accordance with the first or second aspect or a genetic construct in accordance with the third aspect, the process comprising coupling successive nucleotides and/or ligating appropriate oligomers.
The invention also relates to other nucleic acid (including RNA) either corresponding to or complementary to DNA in accordance with the first or second aspects.
Preferred embodiments and examples of the invention will now be described. In the following description, reference is made to a number of drawings, in which:
Figure 1 shows the amino acid sequence of streptavidin;
Figure 2 shows a sequence of a streptavidin synthetic gene in accordance with the invention incorporating a summary of restriction sites;
Figure 3 shows a sequence of a synthetic streptavidin gene in accordance with the invention divided into oligonucleotides; and
Figure 4 shows a summary of an assembly procedure used.
EXAMPLE
CONSTRUCTION OP THE GENE
The des ired gene s equence was d iv ided into 2 4 oligodeoxyribonucleotides (oligomers) as depicted in Figure 3. The division was such as to provide 7 base cohesive ends after annealing complementary pairs of oligomers. The end points of the oligomers were chosen to minimise the potential for inappropriate ligation of oligomers at the assembly stage.
The oligomers were synthesised by automated solid phase phosphoramidite chemistry. Following de-blocking and removal from the controlled pore glass support the oligomers were purified on denaturing polyacrylamide gels, further purified by ethanol precipitation and finally dissolved in water prior to estimation of their concentration.
All the oligomers with the exception of the 5' terminal oligomers BB214 and BB237 were then kinased to provide them with a 5' phosphate as required for the ligation step. Complementary oligomers were then annealed and the 12 pairs of oligomers ligated together by T4 DNA ligase as depicted in Figure 4. The ligation products were separated on a 2% low gelling temperature (LGT) gel and the band corresponding to the 501/501 bp streptavidin gene duplex was cut out and extracted from the gel. The purified fragment was ligated to EcoRI/HindIII cut DNA of the plasmid vector pUC18. The ligated product was transformed into HW87 and plated on L-agar plates containing 100 meg ml-1 ampicillin. Colonies containing potential clones were then grown up in L-broth containing ampicillin at 100 meg ml-1 and plasmid DNA isolated. Positive clones were identified by direct dideoxy sequence analysis of the plasmid DNA using the 17 base universal primer, a reverse sequencing primer complementary to the opposite strand on the other side of the polylinker and some of the oligomers employed in the assembly of the gene that served as internal primers. One streptavidin clone was subsequently re-sequenced on both strands to confirm that no mutations were present.
METHODS
All the techniques of genetic manipulation used in the manufacture of this gene are well known to those skilled in the art of genetic engineering. A description of most of the techniques can be found in the laboratory manual entitled Molecular Cloning by T. Maniatis, E.F. Fritsch and J. Sambrook published by Cold Spring Harbor Laboratory, Box 100, New York.
Additional and modified methodologies are detailed below.
1) Oligonucleotide synthesis
The oligonucleotides were synthesised by automated phosphoramidite chemistry using cyanoethyl phosphoramidtes. The methodology is now widely used and has been described (Beaucage, S.L. and Caruthers, M.H. Tetrahedron Letters 24, 245 (1981)).
2) Purification of Oligonucleotides
The oligonucleotides were de-protected and removed from the CPG support by incubation in concentrated NH3. Typically, 50 mg of CPG carrying 1 micromole of oligonueleotide was de-protected by incubation for 5 hr at 70° in 600 mcl of concentrated NH3. The supernatant was transferred to a fresh tube and the oligomer precipitated with 3 volumes of ethanol. Following centrifugation the pellet was dried and resuspended in 1 ml of water. The concentration of crude oligomer was then determined by measuring the absorbance at 260 nm.
For gel purification 10 absorbance units of the crude oligonucleotide were dried down and resuspended in 15 mcl of marker dye (90% de-ionised formamide, 10mM tris, 10 mM borate, ImM EDTA, 0.1% bromophenol blue). The samples were heated at 90° for 1 minute and then loaded onto a 1.2 mm thick denaturing polyacrylamide gel with 1.6 mm wide slots. The gel was prepared from a stock of 15% acrylamide, 0.6% bisacrylamide and 7M urea in 1 X TBE and was polymerised with 0.1% ammonium persulphate and 0.025% TEMED. The gel was pre-run for 1 hr. The samples were run at 1500 V for 4-5 hr. The bands were visualised by UV shadowing and those corresponding to the full length product cut out and transferred to micro-testubes. The oligomers were eluted from the gel slice by soaking in AGEB (0.5 M ammonium acetate, 0.01 M magnesium acetate and 0.1 % SDS) overnight. The AGEB buffer was then transferred to fresh tubes and the oligomer precipitated with three volumes of ethanol at -70° for 15 min. The precipitate was collected by centrifugation in an Eppendorf microfuge for 10 min, the pellet washed in 80 % ethanol, the purified oligomer dried, redissolved in 1 ml of water and finally filtered through a 0.45 micron micro-filter. The concentration of purified product was measured by determining its absorbance at 260 nm. 3) Kinasing of oligomers
250 pmole of oligomer was dried down and resuspended in 20 mcl kinase buffer (70 mM Tris pH 7.6, 10 mM MgCl2, 1 mM ATP, 0.2 mM spermidine, 0.5 mM dithiothreitol). 10 u of T4 polynucleotide kinase was added and the mixture incubated at 37° for 30 min. The kinase was then inactivated by heating at 85° for 15 min.
4 ) Annealing
8 mcl of each oligomer was mixed, heated to 90° and then slow cooled to room temperature over a period of an hour.
5) Ligation
5 mcl of each annealed pair of oligomers were mixed and 10 X ligase buffer added to give a final ligase reaction mixture (50 mM Tris pH 7.5, 10 mM MgCl2, 20 mM dithiothreitol, 1 mM ATP. T4 DNA ligase was added at a rate of 100 u per 50 mcl reaction and ligation carried out at 15° for 4 hr.
6) Agarose gel electrophoresis
Ligation products were separated using 2% low gelling temperature agarose gels in 1 X TBE buffer (0.094 M Tris pH 8.3, 0.089 M boric acid, 0.25 mM EDTA) containing 0.5 meg ml-1 ethidium bromide. 7) Isolation of ligation product
The band corresponding to the expected streptavidin gene ligation product was identified by reference to size markers under long wave UV illumination. The band was cut out of the gel and the DNA extracted as follows.
The volume of the gel slice was estimated from its weight and then melted by incubation at 65° for 10 min. The volume of the slice was then made up to 400 mcl with TE (10 mM Tris pH 8.0, 1 mM EDTA) and Na acetate added to a final concentration of 0.3 M. 10 meg of yeast tRNA was also added as a carrier. The DNA was then subjected to three rounds of extraction with equal volumes of TE equilibrated phenol followed by three extractions with ether that had been saturated with water. The DNA was precipitated with 2 volumes of ethanol, centrifuged for 10 min in a microfuge, the pellet washed in 70 % ethanol and finally dried down. The DNA was taken up in 20 mcl of TE and 2 mcl run on a 2 % agarose gel to estimate the recovery of DNA.
8) Cloning of fragment
0.5 meg of pUC18 DNA (eg ATCC 37253) was prepared by cleavage with HindIII and BamHI as advised by the suppliers. The digested DNA was run on an 0.8 % LGT gel and the vector band purified as described above.
20 ng of cut vector DNA was then ligated to various quantities of streptavidin DNA ranging from 2 to 20 ng for 4 hr using the ligation buffer described above. The ligation products were used to transform competent HW87 as has been described. Ampicillin resistant transformants were selected on L-agar plates containing 100 meg ml-1 ampicillin.
9) Isolation of plasmid DNA
Plasmid DNA was prepared from the colonies containing potential streptavidin clones essentially as described (Ish-Horowicz, D., Burke, J.F. Nucleic Acids Research 9 2989-2998 (1981).
10) Dideoxy sequencing
The protocol used was essentially as has been described (Biggin, M.D., Gibson, T.J., Hong, G.F. P.N.A.S. 80 3963-3965 (1983)). The method was modified to allow sequencing on plasmid DNA as described (Guo, L-H., Wu, R. Nucleic Acids Research 11 5521-5540 (1983).
11) Transformation
Transformation was accompl ished using standard procedures . The strain used as a recipient in the cloning was HW87 which has the following genotype:
araD139 (ara-leu) del7697 (lacIPOZY) del74 galU galK hsdR rpsL srl recA56
Any other standard cloning recipient such as HB101 would be adequate.

Claims

1. DNA coding for streptavidin and having restriction sites for the following enzymes:
EcoRI, NdeI. PstI. SalI. SacI. SnaBI, BspMI, KpnI. FSPI. PflMI, DraIII, BalI. BstXI, HpaI, NsiI. SoeI. NheI, BstEII, XbaI. BamHI and HindIII
2. DNA including the following sequence:
ATG GAC CCG TCC AAG GAC TCC AAA GCT CAG GTT TCT GCA GCC GAA GCT GGT ATC ACT GGC ACC TGG TAT AAC CAA CTG GGG TCG ACT TTC ATT GTG ACC GCT GGT GCG GAC GGA GCT CTG ACT GGC ACC TAC GAA. TCT GCG GTT GGT AAC GCA GAA TCC CGC TAC GTA CTG ACT GGC CGT TAT GAC TCT GCA CCT GCC ACC GAT GGC TCT GGT ACC GCT CTG GGC TGG ACT GTG GCT TGG AAA AAC AAC TAT CGT AAT GCG GAC AGC GCC ACT ACG TGG TCT GGC CAA TAC GTT GGC GGT GCT GAG GCT CGT ATC AAC ACT CAG TGG CTG TTA ACA TCC GGC ACT ACC GAA GCG AAT GCA TGG AAA TCG ACA CTA GTA GGT CAT GAC ACC TTT ACC AAA GTT AAG CCT TCT GCT GCT AGC ATT GAT GCT GCC AAG AAA GCA GGC GTA AAC AAC GGT AAC CCT CTA GAC GCT GTT CAG CAA TAA
3. A genetic construct comprising DNA as claimed in claim 1 or 2, or a fragment thereof.
4. A construct as claimed in claim 3, wherein the fragment comprises at least 10 nucleotides.
5. A construct as claimed in claim 3, wherein the fragment comprises at least 20 nucleotides.
6. A construct as claimed in claim 3, wherein the fragment comprises at least 30 nucleotides.
7. A construct as claimed in claim 3, wherein the fragment comprises at least 40 nucleotides.
8. A construct as claimed in claim 3, wherein the fragment comprises at least 50 nucleotides.
9. A construct as claimed in claim 3, which is a vector.
10. A genetic construct as claimed in any one of claims 3 to 9 which is or embodies a chimeric gene composing all or a fragment of DNA according to the first or second aspect fused to any other sequence of DNA so as to result in a sequence capable of encoding a hybrid protein possessing biotin binding activity.
11. A process for the preparation of DNA as claimed in claim 1 or 2 or a genetic construct in accordance with claim 3, the process comprising coupling successive nucleotides and/or ligating appropriate oligomers.
12. DNA substantially as herein described with reference to Figure 2.
PCT/GB1988/000831 1987-10-08 1988-10-07 Synthetic gene WO1989003422A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
NO90901588A NO901588L (en) 1987-10-08 1990-04-06 SYNTHETIC GEN.
FI901763A FI901763A0 (en) 1987-10-08 1990-04-06 SYNTHETIC GEN.
DK088290A DK88290A (en) 1987-10-08 1990-04-06 SYNTHETIC GEN

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878723661A GB8723661D0 (en) 1987-10-08 1987-10-08 Synthetic gene
GB8723661 1987-10-08

Publications (1)

Publication Number Publication Date
WO1989003422A1 true WO1989003422A1 (en) 1989-04-20

Family

ID=10624999

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1988/000831 WO1989003422A1 (en) 1987-10-08 1988-10-07 Synthetic gene

Country Status (6)

Country Link
EP (1) EP0390785A1 (en)
JP (1) JPH03501923A (en)
DK (1) DK88290A (en)
FI (1) FI901763A0 (en)
GB (1) GB8723661D0 (en)
WO (1) WO1989003422A1 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2212160B (en) * 1987-11-13 1991-12-11 British Bio Technology Dna sequences encoding the bspmi recognition site.
WO1993009144A1 (en) * 1991-10-28 1993-05-13 Boehringer Mannheim Gmbh Recombinant core-streptavidin
WO1994000992A1 (en) * 1992-07-10 1994-01-20 Pioneer Hi-Bred International, Inc. Avidin and homologues as larvicides against insect pests
WO1997011183A1 (en) * 1995-04-11 1997-03-27 Trustees Of Boston University Streptavidin mutants
WO1997011186A1 (en) * 1995-09-23 1997-03-27 Boehringer Mannheim Gmbh Process for producing natriuretic peptides via streptavidine fusion proteins
WO1997018314A1 (en) * 1995-11-16 1997-05-22 Boehringer Mannheim Gmbh Process for the preparation of peptides by way of streptavidin fusion proteins
US5973116A (en) * 1993-01-15 1999-10-26 Imperial Cancer Research Technology Limited Compounds for targeting
US6156493A (en) * 1995-02-09 2000-12-05 University Of Washington Modified-affinity streptavidin
WO2002072817A1 (en) * 2001-03-12 2002-09-19 Japan Tobacco Inc. Novel protein, gene encoding the same and method of using the same
US6492492B1 (en) 1998-04-03 2002-12-10 University Of Washington Circularly permuted biotin binding proteins
WO2005014650A2 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US6972350B1 (en) 1998-07-15 2005-12-06 The Horticulture And Food Research Institute Of New Zealand Pest-resistant plants comprising a construct encoding a vacuole targeting sequence and avidin or streptavidin
EP2275816A2 (en) 2006-03-22 2011-01-19 Viral Logic Systems Technology Corp. Methods for identifying polypeptide targets and uses thereof for treating immunological diseases
EP2322933A1 (en) 2001-08-29 2011-05-18 Pacific Northwest Research Institute Diagnosis of carcinomas
EP2338906A1 (en) 2003-06-16 2011-06-29 UCB Manufacturing, Inc. Compostion and methods for increasing bone mineralization
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983004053A1 (en) * 1982-05-06 1983-11-24 Applied Molecular Genetics, Inc. The manufacture and expression of large structural genes
WO1986002077A1 (en) * 1984-10-02 1986-04-10 Meade Harry M Production of streptavidin-like polypeptides
WO1987005026A1 (en) * 1986-02-24 1987-08-27 The Trustees Of Columbia University In The City Of Dna encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof
EP0171024B1 (en) * 1984-08-10 1991-09-11 Hoechst Aktiengesellschaft Genetic engineering process for the production of hirudins, and agents for carrying out said process

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983004053A1 (en) * 1982-05-06 1983-11-24 Applied Molecular Genetics, Inc. The manufacture and expression of large structural genes
EP0171024B1 (en) * 1984-08-10 1991-09-11 Hoechst Aktiengesellschaft Genetic engineering process for the production of hirudins, and agents for carrying out said process
WO1986002077A1 (en) * 1984-10-02 1986-04-10 Meade Harry M Production of streptavidin-like polypeptides
WO1987005026A1 (en) * 1986-02-24 1987-08-27 The Trustees Of Columbia University In The City Of Dna encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2212160B (en) * 1987-11-13 1991-12-11 British Bio Technology Dna sequences encoding the bspmi recognition site.
WO1993009144A1 (en) * 1991-10-28 1993-05-13 Boehringer Mannheim Gmbh Recombinant core-streptavidin
AU659240B2 (en) * 1991-10-28 1995-05-11 Boehringer Mannheim Gmbh Recombinant core-streptavidin
WO1994000992A1 (en) * 1992-07-10 1994-01-20 Pioneer Hi-Bred International, Inc. Avidin and homologues as larvicides against insect pests
US5973116A (en) * 1993-01-15 1999-10-26 Imperial Cancer Research Technology Limited Compounds for targeting
US6165750A (en) * 1995-02-09 2000-12-26 University Of Washington Modified-affinity streptavidin
US6156493A (en) * 1995-02-09 2000-12-05 University Of Washington Modified-affinity streptavidin
WO1997011183A1 (en) * 1995-04-11 1997-03-27 Trustees Of Boston University Streptavidin mutants
US6022951A (en) * 1995-04-11 2000-02-08 Univ Boston Streptavidin mutants
US6207390B1 (en) * 1995-04-11 2001-03-27 The Trustees Of Boston University Methods for the use of reduced affinity streptavidin
WO1997011186A1 (en) * 1995-09-23 1997-03-27 Boehringer Mannheim Gmbh Process for producing natriuretic peptides via streptavidine fusion proteins
WO1997018314A1 (en) * 1995-11-16 1997-05-22 Boehringer Mannheim Gmbh Process for the preparation of peptides by way of streptavidin fusion proteins
US6136564A (en) * 1995-11-16 2000-10-24 Roche Diagnostics Gmbh Process for the production of peptides by way of streptavidin fusion proteins
US6492492B1 (en) 1998-04-03 2002-12-10 University Of Washington Circularly permuted biotin binding proteins
US6972350B1 (en) 1998-07-15 2005-12-06 The Horticulture And Food Research Institute Of New Zealand Pest-resistant plants comprising a construct encoding a vacuole targeting sequence and avidin or streptavidin
EP1369476A4 (en) * 2001-03-12 2004-07-28 Japan Tobacco Inc A novel protein, a gene encoding therefor and a method of using the same
EP1369476A1 (en) * 2001-03-12 2003-12-10 Japan Tobacco Inc. A novel protein, a gene encoding therefor and a method of using the same
WO2002072817A1 (en) * 2001-03-12 2002-09-19 Japan Tobacco Inc. Novel protein, gene encoding the same and method of using the same
EP1865059A1 (en) * 2001-03-12 2007-12-12 Japan Tobacco, Inc. A novel protein, a gene encoding therefor and a method of using the same
KR100890839B1 (en) * 2001-03-12 2009-03-27 니뽄 다바코 산교 가부시키가이샤 A novel protein, a genes encoding therefor and a method of using the same
US7713531B2 (en) 2001-03-12 2010-05-11 Japan Tobacco, Inc. Protein, a gene encoding therefor and a method of using the same
US7776333B2 (en) 2001-03-12 2010-08-17 Japan Tobacco Inc. Protein, a genes encoding therefor and a method of using the same
US7855282B2 (en) 2001-03-12 2010-12-21 Japan Tobacco Inc. Protein, a gene encoding therefor and a method of using the same
US7989610B2 (en) 2001-03-12 2011-08-02 Japan Tobacco Inc Protein, a gene encoding therefor and a method of using the same
EP2913673A1 (en) 2001-08-29 2015-09-02 Pacific Northwest Research Institute Diagnosis of ovarian carcinoma
EP2322933A1 (en) 2001-08-29 2011-05-18 Pacific Northwest Research Institute Diagnosis of carcinomas
EP2341071A1 (en) 2003-06-16 2011-07-06 UCB Manufacturing, Inc. Compostion and methods for increasing bone mineralization
EP2338906A1 (en) 2003-06-16 2011-06-29 UCB Manufacturing, Inc. Compostion and methods for increasing bone mineralization
WO2005014650A2 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
EP2322931A2 (en) 2006-03-22 2011-05-18 Viral Logic Systems Technology Corp. Methods for identifying polypeptide targets and uses thereof for treating immunological diseases
EP2275816A2 (en) 2006-03-22 2011-01-19 Viral Logic Systems Technology Corp. Methods for identifying polypeptide targets and uses thereof for treating immunological diseases
US8293500B2 (en) 2006-03-22 2012-10-23 Viral Logic Systems Technology Corp. Methods for identifying polypeptide targets and uses thereof for treating immunological diseases
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders

Also Published As

Publication number Publication date
DK88290A (en) 1990-06-08
GB8723661D0 (en) 1987-11-11
FI901763A0 (en) 1990-04-06
EP0390785A1 (en) 1990-10-10
JPH03501923A (en) 1991-05-09
DK88290D0 (en) 1990-04-06

Similar Documents

Publication Publication Date Title
WO1989003422A1 (en) Synthetic gene
Beall et al. Sequence analysis, transcriptional organization, and insertional mutagenesis of the envA gene of Escherichia coli
Hellinga et al. Nucleotide sequence and high‐level expression of the major Escherichia coli phosphofructokinase
Köster et al. Iron hydroxamate transport of Escherichia coli: nucleotide sequence of the fhuB gene and identification of the protein
Kaster et al. Analysis of a bacterial hygromycin B resistance gene by transcriptional and translational fusions and by DNA sequencing
Lupski et al. Regulation of the rpsU-dnaG-rpoD macromolecular synthesis operon and the initiation of DNA replication in Escherichia coli K-12
US5182376A (en) Dna sequence for horseradish peroxidase c modified for expression in mammalian cells
US4711844A (en) Modified signal peptides
Baty et al. Extracellular release of colicin A is non‐specific.
IE910948A1 (en) Bacterial vectors
DK166681B1 (en) DNA SEQUENCES, DNA SEQUENCES AND DNA OLIGONUCLEOTIDES FOR USE IN THE PREPARATION OF THE FIRST DNA SEQUENCES, HYBRID PLASMIDS CONTAINING DNA SEQUENCE, HOUSE CELLS WITH 2
AU634926B2 (en) Gene synthesis
Lampe et al. Cloned gene encoding the delta subunit of Bacillus subtilis RNA polymerase
Sauter et al. Transcriptional analysis of the gene encoding pyruvate formate‐lyase‐activating enzyme of Escherichia coli
Laoide et al. Bacillus licheniformis alpha-amylase gene, amyL, is subject to promoter-independent catabolite repression in Bacillus subtilis
Lapeyre et al. Cloning of cDNA encoding a 100 kDa nudeolar protein (nucleoline) of Chinese hamster ovary cells
GB2213821A (en) Synthetic gene
GB2210883A (en) Synthetic gene
JPH05219961A (en) Farnesyl diphosphate synthetase and dna sequence coding the enzyme
WO1989003423A1 (en) Synthetic dna sequence coding for human insulin-like growth factor ii
GB2217327A (en) Synthetic gene encoding interleukin-6
GB2223496A (en) Gene encoding human acidic fibroblast growth factor
GB2218420A (en) Synthetic gene encoding interleukin-4
JP3709422B2 (en) Regulators involved in nitrilase gene expression and genes thereof
GB2217328A (en) Synthetic gene encoding interleukin 5

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): DK FI JP NO US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1988908730

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 901763

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1988908730

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1988908730

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1988908730

Country of ref document: EP